A Phase II Study of MK-2206 for Recurrent Malignant Glioma

Trial Profile

A Phase II Study of MK-2206 for Recurrent Malignant Glioma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2011 Status changed from not yet recruiting to withdrawn prior to recruitment, due to Merck undergoing reprioritization of clinical trials, and terminating many in oncology including this one, according to ClinicalTrials.gov.
    • 07 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top